● Live


You are here

Granules India gains on receiving USFDA approval for generic Methylergonovine tablets

  • May-17-2018
  • 9:19:00 Hrs IST

Granules India is currently trading at Rs. 98.20, up by 1.45 points or 1.50% from its previous closing of Rs. 96.75 on the BSE.

The scrip opened at Rs. 97.90 and has touched a high and low of Rs. 98.20 and Rs. 97.65 respectively. So far 1,710 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 157.00 on 18-May-2017 and a 52 week low of Rs. 91.30 on 14-May-2018.

Last one week high and low of the scrip stood at Rs. 98.70 and Rs. 91.30 respectively. The current market cap of the company is Rs. 2,492.00 crore.

The promoters holding in the company stood at 44.94%, while Institutions and Non-Institutions held 17.55% and 37.51% respectively.

Granules India has received an approval from the United States Food & Drug Administration (USFDA) for its Abbreviated New Drug Applications (ANDA) for Methylergonovine 0.2 mg Tablets. The ANDA was filed by Granules Pharmaceuticals Inc., a wholly owned subsidiary of Granules India. The approved ANDA is the bioequivalent to the reference listed drug product (RLD), Methergine 0.2 MG.

Methylergonovine is a semi-synthetic ergot alkaloid used for the prevention and control of postpartum haemorrhage.

Granules India is manufacturer and supplier of pharmaceutical products. Its products include active pharmaceutical ingredients (API) like tablets, caplets, rapid release, pharmaceutical, formulation intermediates (PFI) and Finished Dosages (FDs).